(Q28165262)

Crossref

https://api.crossref.org/works/10.1007%2FS11926-003-0023-7

Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-003-0023-7

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-003-0023-7

Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men

21 January 2018

1 reference

12 December 2020

The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

1 reference

12 December 2020

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

1 reference

12 December 2020

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

12 December 2020

Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment

1 reference

12 December 2020

Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus

1 reference

12 December 2020

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

1 reference

12 December 2020

Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients

1 reference

12 December 2020

Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis

1 reference

12 December 2020

Warfarin, aspirin, or both after myocardial infarction

1 reference

12 December 2020

Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment.

1 reference

12 December 2020

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

12 December 2020

High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin

1 reference

12 December 2020

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

1 reference

12 December 2020

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 reference

12 December 2020

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.

1 reference

12 December 2020

Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators

1 reference

12 December 2020

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

1 reference

12 December 2020

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

1 reference

12 December 2020